Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Mar 21;13:1759720X21999564. doi: 10.1177/1759720X21999564

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© The Author(s), 2021

This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access page (https://us.sagepub.com/en-us/nam/open-access-at-sage).

PMC Copyright notice

Figure 4. — Comparisons for ACR20 and discontinuations for AEs in the network meta-analysis.

The numbers below the diagonal represent the ORs and 95% CrI of ACR20. ORs higher than 1 indicate that the drug in that column is better than the drug in that row (i.e. favor the upper treatment). The numbers above the diagonal represent the ORs and 95% CrI of discontinuations for AEs. ORs lower than 1 indicate that the drug in that row is better than the drug in that column (i.e. favor the upper treatment). Significant results are in bold and underscored.

ABT, abatacept; ACR20, American College of Rheumatology 20% response; ADA, adalimumab; AEs, adverse events; Bar, baricitinib; CrI, credible interval; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; CZP, certolizumab pegol; ETN, etanercept; GOL, golimumab; IFX, infliximab; ORs, odds ratios; PBO, placebo; RTX, rituximab; TCZ, tocilizumab; Tof, tofacitinib; Upa, upadacitinib.